**3. Conclusion**

Although we show promising data proving the efficacy of bozepinib over CSCs, the mechanism by which bozepinib inhibits the CSC growth requires further detailed investigation. Moreover, the in vivo antitumor and anti-metastatic effect and the non-systemic toxicity of bozepinib encourage further studies on the therapeutic potential of this synthetic compound in breast and colon cancer patients.

The detection of CSCs in multiple solid tumors over the past years represents a paradigm shift in oncology and will probably change our understanding of the tumourigenic process. The impressive number of publications that have appeared in this field in recent years bears testimony to its enormous current interest.

We expect this chapter to stimulate fresh activity within the medicinal chemistry community and to result in the enlargement of chemical structures active against CSCs.

**137**

**Author details**

University of Granada, Granada, Spain

University of Granada, Granada, Spain

provided the original work is properly cited.

\*Address all correspondence to: jmcampos@ugr.es

*Bozepinib: A Promising Selective Derivative Targeting Breast Cancer Stem Cells*

Joaquín M. Campos1,2\*, Ana Conejo-García1,2 and Olga Cruz-López1,2

1 Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy,

2 Granada Biosanitary Institute (ibs. GRANADA), Andalusian Health Service,

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

*DOI: http://dx.doi.org/10.5772/intechopen.91423*
